Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1075
- Registration Number
- NCT00699374
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 45
- Registration Number
- NCT00696696
- Locations
- 🇺🇸
Desert Regional Medical Center, Palm Springs, California, United States
🇺🇸Bellevue Hospital, New York, New York, United States
🇺🇸New York University Cancer Center, New York, New York, United States
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00694291
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 723
- Registration Number
- NCT00678392
- Locations
- 🇺🇸
LAC-USC Medical Center, Los Angeles, California, United States
🇺🇸Ronald Regan UCLA Medical Center, Los Angeles, California, United States
🇺🇸USC Norris Cancer Hospital and Clinics, Los Angeles, California, United States
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT00665990
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- PD Dr Markus Möhler
- Target Recruit Count
- 103
- Registration Number
- NCT00661830
- Locations
- 🇩🇪
Klinikum der Johannes Gutenberg-Universität Mainz, I. Med. Klinik, Mainz, Rheinland-Pfalz, Germany
🇩🇪Universitätsklinikum Jena, Klinik für Innere Medizin, Innere Medizin II, D-07740 Jena, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, I. Med. Klinik, Zentrum für Innere Medizin, Martinistr. 3, D-20248 Hamburg, Germany
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 59
- Registration Number
- NCT00654238
- Locations
- 🇺🇸
University of Pennsylvania - Abramson Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 35
- Registration Number
- NCT00639262
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 36
- Registration Number
- NCT00635791
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 52
- Registration Number
- NCT00634634
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cooper Hospital/University Medical Center, Voorhees, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.